Canadian topical drug developer Crescita Therapeutics (TSX:CTX) said today that it has acquired INTEGA Skin Sciences, a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products.
The share-based transaction is valued at around $8 million, payable in Crescita common shares valued at $2.44 a share, with a further $2 million payable on the achievement of milestones.
INTEGA, financially backed by Knight Therapeutics (TSX:GUD) and Bloom Burton Healthcare Lending Trust, owns the Canadian distribution rights for a number of well-known and established skin care brands, including Laboratoire Dr Renaud.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze